Publicaciones científicas
International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas
Efstathios Kastritis 1, Shaji K Kumar 2, Vincent S Rajkumar 2, Wee Joo Chng 3, Luciano Costa 4, Monika Engelhardt 5, Wilson Gonsalves 2, Vania Hungria 6, Jens Hillengass 7, Dragan Jevremovic 8, Eirini Katodritou 9, Sigurður Yngvi Kristinsson 10, Sagar Lonial 11, Heinz Ludwig 12, Philip McCarthy 13, Elias Mai 14, Salomon Manier 15, Tom Martin 16, Maria-Victoria Mateos 17, Hira Mian 18, Joseph Mikhael 19, Philippe Moreau 20, Nikhil C Munshi 21 22, Bruno Paiva 23, Charlotte Pawlyn 24 25, Leo Rasche 26, Joshua Richter 27, Jesús San Miguel 23, Douglas W Sborov 28, Saad Z Usmani 29, Meletios A Dimopoulos 1 30, Elena Zamagni 31 32
Abstract
Solitary plasmacytomas (SPs) are rare localized tumors of clonal plasma cells, either in the bone (solitary bone plasmacytoma) or in soft tissue/extraosseous (extramedullary) with either no or with minimal bone marrow (BM) infiltration (<10% clonal plasma cells by immunohistochemistry) and no evidence of systemic involvement or myeloma defining events. Approximately 50% of SPs will progress to symptomatic myeloma within 5 years after initial definitive local radiotherapy. Increased availability of improved diagnostic and monitoring tools has increased the sensitivity of detection of additional lesions and marrow involvement and has implications for the follow-up strategy after treatment. Thus, the definitions and requirements for the diagnosis and follow-up of SPs are evolving. The diagnosis of SP requires the careful exclusion of multiple myeloma (MM) that would require systemic therapy, by using all the available methods to detect systemic disease (advanced imaging, sensitive BM assessment methods, blood and urine tests). Local radiotherapy remains the mainstay of therapy, and despite the availability of innovative drugs for MM, the clinical benefit of systemic therapy currently remains poorly defined. The International Myeloma Working Group provides here updated recommendations for the diagnosis, evaluation, treatment, and response assessment of patients with SPs, incorporating recent data and advances in diagnostic tools.
CITA DEL ARTÍCULO J Clin Oncol. 2026 Sep;44(25):2447-2459. doi: 10.1200/JCO-26-00410.
Nuestros autores
